Drug intelligence / Profile preview

fluocinolone acetonide + hydroquinone + tretinoin

Development stage
Approved
Lead developer
Galderma
Modality
Small Molecules
Administration
Topical
01

Overview

**Fluocinolone acetonide + hydroquinone + tretinoin** is a prescription fixed-dose topical triple-combination cream containing fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05%. Fluocinolone acetonide is a topical corticosteroid that reduces local inflammation and irritation; hydroquinone reduces melanin production through inhibition of tyrosinase activity; and tretinoin is a retinoid that activates retinoic acid receptors, promotes epidermal turnover, and enhances depigmenting activity. The marketed product Tri-Luma is approved in the United States for short-term treatment of moderate-to-severe facial melasma alongside sun avoidance and sunscreen use. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a35fa709-5eb5-4429-b38f-f1e0019bf0ee))

Brand names
Tri-Luma
Other names
fluocinolone acetonide, hydroquinone, and tretinoinfluocinolone acetonide/hydroquinone/tretinoin
02

Targets

TYR (Tyrosinase)RAR (Retinoic acid receptor)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on fluocinolone acetonide + hydroquinone + tretinoin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluocinolone acetonide + hydroquinone + tretinoin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call